Completed PHASE3 INTERVENTIONAL 1-arm NCT02366962

A Study to Assess the Safety of ASP7374 in Adult Subjects Aged 20 or Older

Phase III Study of ASP7374-Open-label Study of Subcutaneous Vaccination of Quadrivalent ASP7374 in Adult Subjects Aged 20 or Older

Sponsor: UMN Pharma Inc.

Conditions Influenza Vaccine

Interventions ASP7374

Updated 7 times since 2017 Last updated: Sep 27, 2017 Started: Feb 28, 2015 Primary completion: Apr 30, 2015 Completion: Apr 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Influenza and Vaccine, this trial is completed. The trial is conducted by UMN Pharma Inc. and has accumulated 7 data snapshots since 2015. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Sep 2020 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — Sep 2020 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Oct 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Oct 2017 [monthly]

Completed PHASE3

First recorded

Feb 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

UMN Pharma Inc.

Data source: UMN Pharma Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Fukuoka, Japan